StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Goldman Sachs Downgrades Alnylam Pharmaceuticals (ALNY) to Buy
August 13, 2018 3:25 AM
(Updated - August 13, 2018 4:02 AM EDT)
(updated to add analyst comment)Goldman Sachs analyst Terrance Flynn downgraded Alnylam ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Hot Downgrades
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Lowered to $123 at Stifel
August 13, 2018 7:16 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $147 at Cowen on Strict Label
August 13, 2018 6:57 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data
August 13, 2018 6:35 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $230 at B.Riley/FBR
August 13, 2018 2:51 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $198 at JMP Securities
August 13, 2018 1:54 AM
Alnylam Pharma (ALNY) Says Annual List Price for Onpattro is $450,000; With Discounts $345,000 - Bloomberg, Citing Conf. Call
August 10, 2018 3:17 PM